The Technical Analyst
Pasithea Therapeutics [KTTA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Pasithea Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.14% $7.11
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 7.41 mill |
| EPS: | -12.64 |
| P/E: | -0.560 |
| Earnings Date: | May 12, 2024 |
| SharesOutstanding: | 1.042 mill |
| Avg Daily Volume: | 0.0051 mill |
| RATING 2024-04-18 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.560 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.10x |
| Company: PE -0.560 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$13.25 (86.32%) $6.14 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 6.75 - 7.48 ( +/- 5.13%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-01 | Marques Tiago | Buy | 15 000 | Stock Option (right to buy) |
| 2024-03-01 | Marques Tiago | Buy | 11 669 | Stock Option (right to buy) |
| 2024-03-01 | Dumesnil Simon | Buy | 7 500 | Stock Option (right to buy) |
| 2024-03-01 | Schneiderman Daniel H | Buy | 10 000 | Stock Option (right to buy) |
| 2024-03-01 | Schneiderman Daniel H | Buy | 5 927 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 3.61 |
| Last 66 transactions |
| Buy: 2 674 808 | Sell: 1 100 000 |
Forecast:
11:37 - $7.10
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $7.11 (-0.14% ) |
| Volume | 0.0005 mill |
| Avg. Vol. | 0.0051 mill |
| % of Avg. Vol | 10.11 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For KTTA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
KTTA
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Latest Press Releases
2024-02-13 07:59:00 - Press Release
Pasithea Therapeutics Announces Opening Of Enrollment In The U.s. For Its Phase 1 Trial Of Pas-004
-- activation of four u.s. sites for phase 1 clinical trial of pas-004 to evaluate safety, dose, key biomarker data and preliminary efficacy -- -- plans to open three additional sites in eastern europe in the coming months -- -- preliminary interim data expected in 2h 2024 -- south san francisco, calif. and miami, feb. 13, 2024 (globe newswire) -- pasithea therapeutics corp. (nasdaq: ktta) (“pasithea” or the “company”), a clinical-stage biotechnology company developing pas-004, a next-generation macrocyclic mek inhibitor, for the treatment of neurofibromatosis type 1 (nf1) and other cancer indications, today announced the activation of four clinical trial sites in the united states.
2024-01-08 07:59:00 - Press Release
Pasithea Therapeutics Announces Invention Of Crystalline Form Of Pas-004; Establishes Strengthened Intellectual Property (ip) Position
-- polymorph and stereoisomer patents when issued extend portfolio to at least 2045 -- -- polymorph and stereoisomer patent filings continue to expand patent portfolio -- south san francisco, calif. and miami, jan. 08, 2024 (globe newswire) -- pasithea therapeutics corp. (nasdaq: ktta) (“pasithea” or the “company”), a clinical stage biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (cns) disorders, today announced the invention of a crystalline form of pas-004 which is captured in polymorph and stereoisomer patent filings that when issued we believe will extend patent protection to at least 2045.
2024-01-02 08:35:00 - Press Release
Pasithea Therapeutics Announces Fda Acceptance Of Ind Application To Evaluate Pas-004 In Advanced Cancer Patients
-- pas-004 is the first macrocyclic mek inhibitor to enter human clinical trials -- -- phase 1 dose escalation study in patients with mapk pathway driven advanced solid tumors to begin in q1 2024 – -- initial readout expected as early as q3 2024 – south san francisco, calif. and miami, jan. 02, 2024 (globe newswire) -- pasithea therapeutics corp. (nasdaq: ktta) (“pasithea” or the “company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (cns) disorders, today announced the investigational new drug application (ind) clearance to proceed by the u.s. federal drug administration (fda) to evaluate pas-004, a macrocyclic mek (1/2) inhibitor, in patients with mapk pathway driven advanced solid tumors with a documented ras, raf or nf1 mutation or patients who have failed braf/mek inhibition.
2023-12-28 17:00:00 - Press Release
Pasithea Therapeutics Announces Adjournment Of Reconvened Meeting Of Stockholders To December 29, 2023
Pasithea therapeutics (nasdaq: ktta) adjourns stockholder meeting again to dec 29 for voting on charter amendments, after partial adjournment on dec 19.
2023-12-19 17:19:00 - Press Release
Pasithea Therapeutics Announces Results From 2023 Annual Meeting
South san francisco, calif. and miami, dec. 19, 2023 (globe newswire) -- pasithea therapeutics corp. (“pasithea” or the “company”) (nasdaq: ktta), today announced that it held its annual meeting of stockholders (the “annual meeting”) on december 19, 2023.
Latest News
2023-12-13 09:03:25 - InvestorPlace
Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?
Pasithea Therapeutics (NASDAQ: KTTA ) stock is falling on Wednesday after the company's shares experienced major volatility on Tuesday. Investors watching KTTA stock will note that it closed out Tuesday up less than 1%.
2023-12-11 11:18:11 - InvestorPlace
Why Is Pasithea Therapeutics (KTTA) Stock Up 105% Today?
Pasithea Therapeutics (NASDAQ: KTTA ) stock is rocketing higher on Monday after the biotechnology company announced results from two preclinical trials of PAS-004. The first study saw positive results from PAS-004 as a treatment for lung cancer.
2023-09-07 16:14:00 - GlobeNewsWire
Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference
-- Attendees may request 1 x 1 meeting with management at meetings@hcwco.com -- PALO ALTO, Calif. and MIAMI, Fla., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, announced today that Pasithea's management team will participate in the H.C. Wainwright 25th Annual Global Investment Conference, to be held in New York City, September 11-13.
2021-12-29 16:16:41 - PennyStocks
Hot Penny Stocks For Your January 2022 Watchlist
Making a penny stocks watchlist for January? Check these three out The post Hot Penny Stocks For Your January 2022 Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-12-23 13:58:28 - PennyStocks
Top Penny Stocks to Watch During Today's Bull Run
Can these three penny stocks continue to make gains next month? The post Top Penny Stocks to Watch During Today's Bull Run appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-12-23 11:35:27 - InvestorPlace
KTTA Stock Alert: 6 Things to Know About Pasithea Therapeutics as Shares Soar Today
Pasithea Therapeutics (KTTA) stock is heading higher on heavy trading Thursday even without any recent news from the biotech company. The post KTTA Stock Alert: 6 Things to Know About Pasithea Therapeutics as Shares Soar Today appeared first on InvestorPlace.
2021-11-24 06:07:21 - Pulse2
Pasithea Therapeutics (KTTA) Stock: Why The Price Jumped Today
The stock price of Pasithea Therapeutics Corp (NASDAQ: KTTA) increased by over 25% pre-market today. This is why it happened.
2021-11-23 09:35:26 - PennyStocks
Hot Penny Stocks Today: Why Is KTTA Stock Moving?
Shares of penny stock KTTA are on the move and here's what's going on. The post Hot Penny Stocks Today: Why Is KTTA Stock Moving?
2021-11-23 08:41:23 - Pulse2
Pasithea Therapeutics (KTTA) Stock: Why The Price Surged Today
The stock price of Pasithea Therapeutics Corp (NASDAQ: KTTA) increased by over 135% pre-market today. This is why it happened.
2021-10-14 09:13:32 - Benzinga
Pasithea Therapeutics Opens its First Ketamine Therapy Clinic in the United Kingdom
Pasithea Clinics partners with ZEN Healthcare – a network of health clinics in Central London – to offer ketamine infusion therapy for the treatment of mental health disorders Ketamine in sub-anesthetic doses has shown to be highly effective at treating some psychiatric disorders, such as treatment resistant depression and post-traumatic stress disorder